Chiara M Cattaneo
Overview
Explore the profile of Chiara M Cattaneo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
772
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Coelho M, Strauss M, Watterson A, Cooper S, Bhosle S, Illuzzi G, et al.
Nat Genet
. 2024 Oct;
56(11):2479-2492.
PMID: 39424923
Drug resistance is a principal limitation to the long-term efficacy of cancer therapies. Cancer genome sequencing can retrospectively delineate the genetic basis of drug resistance, but this requires large numbers...
2.
Vennin C, Cattaneo C, Bosch L, Vegna S, Ma X, Damstra H, et al.
Cancer Cell
. 2023 Jun;
41(6):1170-1185.e12.
PMID: 37311414
Although treatment with taxanes does not always lead to clinical benefit, all patients are at risk of their detrimental side effects such as peripheral neuropathy. Understanding the in vivo mode...
3.
Coelho M, Cooper S, Strauss M, Karakoc E, Bhosle S, Goncalves E, et al.
Cancer Cell
. 2023 Jan;
41(2):288-303.e6.
PMID: 36669486
Interferon-γ (IFN-γ) signaling mediates host responses to infection, inflammation and anti-tumor immunity. Mutations in the IFN-γ signaling pathway cause immunological disorders, hematological malignancies, and resistance to immune checkpoint blockade (ICB)...
4.
Cattaneo C, Battaglia T, Urbanus J, Moravec Z, Voogd R, de Groot R, et al.
Nat Biotechnol
. 2023 Jan;
41(6):783-787.
PMID: 36593398
Cancer neoantigens that arise from tumor mutations are drivers of tumor-specific T cell responses, but identification of T cell-recognized neoantigens in individual patients is challenging. Previous methods have restricted antigen...
5.
Amodio V, Lamba S, Chila R, Cattaneo C, Mussolin B, Corti G, et al.
Cancer Cell
. 2022 Dec;
41(1):196-209.e5.
PMID: 36584674
Patients affected by colorectal cancer (CRC) with DNA mismatch repair deficiency (MMRd), often respond to immune checkpoint blockade therapies, while those with mismatch repair-proficient (MMRp) tumors generally do not. Interestingly,...
6.
Booij T, Cattaneo C, Hirt C
Cells
. 2022 Nov;
11(21).
PMID: 36359838
Organoid models allow for the study of key pathophysiological processes such as cancer biology in vitro. They offer insights into all aspects covering tumor development, progression and response to the...
7.
Picco G, Cattaneo C, van Vliet E, Crisafulli G, Rospo G, Consonni S, et al.
Cancer Discov
. 2021 Apr;
11(8):1923-1937.
PMID: 33837064
Targeted therapies, chemotherapy, and immunotherapy are used to treat patients with mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer. The clinical effectiveness of targeted therapy and chemotherapy is limited by resistance...
8.
Cattaneo C, Dijkstra K, Fanchi L, Kelderman S, Kaing S, van Rooij N, et al.
Nat Protoc
. 2019 Dec;
15(1):15-39.
PMID: 31853056
T cells are key players in cancer immunotherapy, but strategies to expand tumor-reactive cells and study their interactions with tumor cells at the level of an individual patient are limited....
9.
Dijkstra K, Cattaneo C, Weeber F, Chalabi M, van de Haar J, Fanchi L, et al.
Cell
. 2018 Aug;
174(6):1586-1598.e12.
PMID: 30100188
Cancer immunotherapies have shown substantial clinical activity for a subset of patients with epithelial cancers. Still, technological platforms to study cancer T-cell interactions for individual patients and understand determinants of...